Aug 16, 2023: New US DB profile with ~300 Million records added!

Started in 2014, STATinMED’s licensed all-payer medical, and pharmacy claims dataset (STATinMED Real World Data Insights) provides insight into approximately 80% of the US healthcare system. These data are comparable with other all-payer claims repositories as they are sourced directly from claims clearinghouses, which are responsible to manage claims transactions between payers and providers, offering comprehensive coverage at the patient level across the US healthcare system.

STATinMED Real World Data Insights (USA)

Database Contact Data

Keshia Maughn
SVP/Principal, RWE (STATinMED RWD Insights)
STATinMED, LLC
13101 Preston Rd Suite 110, #3395
Dallas, TX 75240
USA
Phone:+1 214-480-4946
Email: kmaughn@statinmed.com

Alternate Contact

STATinMED RWD Insights
Amy Rovi, SVP, Sales and Marketing
STATinMED, LLC
13101 Preston Rd Suite 110, #3395 
Dallas, TX 75240
USA
Phone: +1 214-480-4946
Email: arovi@statinmed.com

References of Studies Using/Describing Database

1. Navari RM, Nelson WW, Shoaib S, Singh R, Zhang W, Bailey WL. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 Jul;40(7):3217-3226.

2. Escobar M, Bullano M, Mokdad AG, Caicedo J, Schultz BG, Fan Q, Verma S. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol. 2023 Jun;16(6):467-474.

3. Terrault N, Dieyi C, Trivedi R, Coppola R, Maynard J, Reau N, Satram S, Chattergoon M. Prevalence of hepatitis B and D virus among a nationally representative insured population in the United States. AASLD The Liver Meeting. Boston, MA: Nov 10-14, 2023.

4. Karlitz J, Liu Y, Gupta P, Aweh G, Chung K. Burden of liver cancer among Medicaid-insured patients: A retrospective analysis of a national all-payer claims database. American College of Gastroenterology (ACG) Annual Scientific Meeting. Vancouver, CA: Oct 20-25, 2023.

5. Holman D, Drayton D, Pandit M, Diaz A, Maughn K, Dieyi C, Achter E, Peeples H. Effects of insurance coverage and antiseizure medication formulary policies on the experiences of patients with epilepsy and healthcare professionals: A qualitative study. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

6. Chung KC, Karlitz J, Liu Y, Gupta P, Aweh G. Cancer incidence among the Medicaid population: A retrospective analysis of a national all-payer claims database. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

7. Hendrix K, Feliciano J, Wassel C, Feld A, Maynard J, Batchu L, Lauterio M, Mohanty M, Dasenbrook E. Real-world disease burden and mortality associated with bronchiectasis. American College of Chest Physicians (CHEST) Annual Meeting. Honolulu, HI: Oct 8-11, 2023.

8. Sarafoglou K, Casteras A, Charlton RW, Barnes C, Dieyi C, Thornton P. Dose dependent risks of glucocorticoid treatment in classic CAH. European Society for Paediatric Endocrinology (ESPE). Hague, Netherlands: Sept 21-23, 2023.

9. Jagannath S, Kharat A, Fu AZ, Huo S, Kohli M, Adams S, Umeh E, Foster M. Healthcare resource utilization and costs among patients with relapsed/refractory multiple myeloma treated with chimeric antigen receptor-T (CAR-T) cell therapy. Annual Meeting of the Society of Hematologic Oncology (SOHO) 2023. Houston, TX: Sept 6-9, 2023.

10. Aksamit T, Wu J, Hassan M, Achter E, Chatterjee A. Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings. BMC Pulm Med. 2022 Dec 3;22(1):461.

Aug 10, 2023: Some of our Board Members are heading to ICPE, and 15 years = 15% discount!

-    Meet three of our Board members attending ICPE in Halifax;
-    It’s our 15th birthday, and you get 15% off your first subscription;
-    We are more than just a database resource – we provide database landscaping services;
-    Complete a 2-minute survey and tell us how we can better assist you!
Read more in our latest newsletter

Aug 1, 2023: We have a new vaccine profile

The Norwegian Immunisation Registry SYSVAK (national vaccination register) is a nationwide electronic vaccination register established in 1995. Until October 2009, the reporting obligation to SYSVAK only covered vaccines given in the childhood vaccination programme. During the flu pandemic in 2009, reporting was also introduced for the vaccine against pandemic flu. Starting January 2011, the reporting obligation was extended to apply to all vaccinations for all age groups in the population.

Norwegian Immunisation Registry (SYSVAK) (Norway) **

Database Contact Data

All enquiries regarding the disclosure of health data should be directed to the e-mail address: datatilgang@fhi.no

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Dong L, Nygård M, Støer NC, Klungsøyr O, Hansen BT. Real‐world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination. International Journal of Cancer. 2023 Jul 15;153(2):399-406.

2. Nilsen TS, Gulseth HL, Daae A, Indseth T. Coronavirus immunisation abroad among foreign-born persons in Norway. Tidsskrift for Den norske legeforening. 2022 Jun 27.

3. Hagerup-Jenssen M, Kongsrud S, Riise ØR. Suboptimal MMR2 vaccine coverage in six counties in Norway detected through the national immunisation registry, April 2014 to April 2017. Euro Surveill. 2017 Apr 27;22(17):30518.

4. Riise ØR, Laake I, Bergsaker MA, Nøkleby H, Haugen IL, Storsæter J. Monitoring of timely and delayed vaccinations: a nation-wide registry-based study of Norwegian children aged < 2 years. BMC Pediatr. 2015 Nov 13;15:180.

5. Riise O. 1066: Delay in the Norwegian Immunisation Programme. Open Forum Infect Dis. 2014 Dec;1(Suppl 1):S312–3.

6. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013 Dec 16;31(52):6232-8.

7. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register--SYSVAK. Euro Surveill. 2012 Apr 19;17(16):20147.

8. Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine. 2012 Jan 11;30(3):544-51.

9. Guzmán Herrador BR, Aavitsland P, Feiring B, Riise Bergsaker MA, Borgen K. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. BMC Infect Dis. 2012 Mar 20;12:63.

10. Waalen K, Kilander A, Dudman S G, Krogh G H, Aune T, Hungnes O. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill. 2010;15(31):pii=19633.

TURKBIO (Turkey) **

Database Contact Data

Fatoş Önen
Division of Rheumatology
Dokuz Eylül University School of Medicine
İzmir
TURKEY
Email: Fatos.onen@gmail.com

Alternate Contact

TÜRK ROMATOLOJİ VERİTABANI "TÜRKBİO"
Dokuz Eylül Üniversitesi Tıp Fakültesi Hastanesi
İç Hastalıkları Ana Bilim Dalı
Romatoloji Bilim Dalı
Balçova
İzmir
TURKEY
Phone: +90 2324123721 
Email: turkbio@zitelab.eu

References of Studies Using/Describing Database

1. Karakaş A, Gulle S, Can G, Dalkılıc E, Akar S, Koca SS, Pehlivan Y, Senel S, Tufan A, Ozturk MA, Yilmaz S, Yazici A, Cefle A, Yüce İnel T, Erez Y, Sari I, Birlik M, Direskeneli H, Akkoc N, Onen F. Does obesity affect treatment response to secukinumab and its survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry. Mod Rheumatol. 2023 Jun 22:road061. doi: 10.1093/mr/road061. Epub ahead of print. 

2. azici A, Özdemir Işık Ö, Dalkılıç E, Koca SS, Pehlivan Y, Şenel S, Inanc N, Akar S, Yılmaz S, Soysal Gündüz Ö, Cefle A, Karakaş ÖF, Onen F. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. Sci Rep. 2022 Dec 20;12(1):21972. 

3. Önen F, Can G, Çapar S, Dalkılıç E, Pehlivan Y, Şenel S, Akar S, Koca SS, Tufan A, Yazıcı A, Yılmaz S, İnanç N, Sarı İ, Birlik M, Solmaz D, Cefle A, Öztürk MA, Yolbaş S, Krogh NS, Yılmaz N, Erten Ş, Bes C, Gündüz ÖS, Göker B, Haznedaroğlu S, Yavuz Ş, Yildirim Çetin G, Yıldız F, Direskeneli H, Akkoç N. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry. Eur J Rheumatol. 2022 Apr;9(2):82-87.

4. Michelsen B, Lindström U, Codreanu C, Ciurea A, Zavada J, Loft AG, Pombo-Suarez M, Onen F, Kvien TK, Rotar Z, Santos MJ, Iannone F, Hokkanen AM, Gudbjornsson B, Askling J, Ionescu R, Nissen MJ, Pavelka K, Sanchez-Piedra C, Akar S, Sexton J, Tomsic M, Santos H, Sebastiani M, Österlund J, Geirsson AJ, Macfarlane G, van der Horst-Bruinsma I, Georgiadis S, Brahe CH, Ørnbjerg LM, Hetland ML, Østergaard M. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020 Sep;6(3):e001280. 

5. Michelsen B, Ørnbjerg LM, Kvien TK, Pavelka K, Nissen MJ, Nordström D, Santos MJ, Koca SS, Askling J, Rotar Z, Gudbjornsson B, Codreanu C, Loft AG, Kristianslund EK, Mann HF, Ciurea A, Eklund KK, Vieira-Sousa E, Yazici A, Jacobsson L, Tomšič M, Löve TJ, Ionescu R, van der Horst-Bruinsma IE, Iannone F, Pombo-Suarez M, Jones GT, Hyldstrup LH, Krogh NS, Hetland ML, Østergaard M. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology (Oxford). 2020 Sep 1;59(9):2455-2461.

6. Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford). 2020 Jul 1;59(7):1640-1650. 

7. Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, Kristianslund EK, Nordström D, Santos MJ, Codreanu C, Gómez-Reino J, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Pavelka K, Birlik M, Kvien T, Eklund KK, Barcelos A, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Loft AG, van der Horst-Bruinsma I, Jones G, Iannone F, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019 Nov;78(11):1536-1544. 

8. Uslu S, Can G, Senel S, Dalkilic E, Inanc N, Akar S, Kocaer SB, Birlik M, Capar S, Akkoc N, Onen F. THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry. Annals of the Rheumatic Diseases. 2018 Jun 1;77:329.

9. Zengin B, Inanç N, Akar S, et alAB0482 Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the turkbio registryAnnals of the Rheumatic Diseases 2018;77:1401-1402.

10. Inanc N, Ozen G, Yalcinkaya Y, et alFRI0134 Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?Annals of the Rheumatic Diseases 2018;77:611-612.

Jul 25, 2023: We finally have the NCARDRS profile! (It includes information from 8 former individual congenital anomaly registries)

Launched April 1, 2015, the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) records information on people with congenital abnormalities and rare diseases across the whole of England. NCARDRS includes information from the following registries, which individually collected data in the past:

- Congenital Anomaly Register for Oxfordshire, Berkshire and Buckinghamshire (CAROBB)

Jul 29, 2023: We have just added a new profile from the Republic of Ireland

The National Cancer Registry of Ireland (NCRI) was established in 1991 and has been collecting comprehensive cancer information for the population of the Republic of Ireland since 1994. This information is used in research into the causes of cancer, in education and information programmes, and in the planning and management of cancer services to deliver the best cancer care to the whole population.

Subscribe to